Ocular (OCUL) Plunges 28 percent

Shares of Ocular Therapeutix, Inc. (OCUL) are down 28% in after hours trading after the company said its lead eye drug failed to meet one of the main goals in a second late-stage study. The drug, OTX-DP (Sustained Release Dexamethasone, 0.4mg), was effective in reducing pain in patients who had cataract surgery, but failed to […] View the full post at: Ocular (OCUL) Plunges 28 percent No related posts.